How to measure visceral fat

How to Measure Visceral Fat When the Scale Says You’re Fine

Visceral fat is imaged directly on CT or MRI. Bioimpedance body composition separates fat mass from lean mass, and blood work such as fasting glucose, insulin, lipids and liver enzymes shows what the depot is doing downstream; weight and body mass index cannot locate it.

Your weight and body mass index cannot show where your fat sits or whether it has turned into immune tissue. Location predicts the harm, and location has to be measured.

Knowing how to measure visceral fat matters more than knowing what you weigh, because the fat packed around your intestines and liver behaves like an immune organ, and it can be inflamed in a person whose scale reading looks ordinary. In the video Your Immune System Is Not Confused, from The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, that fat is one part of a larger argument about Crohn’s disease and a chronic immune load. Here the question is narrower and practical: what would show that load in you, what a routine visit checks, and what it leaves out.

Why doesn’t a normal weight rule out visceral fat?

For years I told people with borderline blood sugar that their numbers were not too bad, and a normal weight made that sentence easier to say. It was the wrong reassurance. Weight is a total. It says nothing about where fat is stored or what the cells inside it are doing.

In the fat of lean mice and lean humans, macrophages, the immune system’s cleanup cells, make up under 10% of the cells. In the most obese mice they pass 50%. In people, the better predictor of that crowding was not body mass index but the size of the individual fat cells, at r² = 0.86 against 0.43 for body mass index. Swollen fat cells are the ones that struggle first, and resident immune cells arrive to help. That help becomes a steady inflammatory signal: more than 90% of what fat tissue releases, apart from the hormones adiponectin and leptin, comes from the immune and support cells living in it, not from the fat cells.

What makes visceral fat dangerous?

In people with obesity, the omental fat that hangs inside the abdomen carried twice as many macrophages as fat under the skin, and that omental burden tracked fasting glucose, insulin sensitivity and liver injury. This fat drains through the portal vein to the liver. In severely obese adults sampled during bariatric surgery, portal blood carried about 50% more interleukin-6, an inflammatory messenger, than arterial blood. Your liver gets the first and strongest dose.

The pattern holds when weight is taken out of the picture. In omental biopsies from women having endometrial cancer surgery, dying fat cells surrounded by macrophages were found in 48% of samples, and they went with diabetes rather than body mass index. In an imaging cohort of 3,086 adults with a mean age of 50.2, more visceral fat meant higher risk of heart and blood vessel disease (hazard ratio 1.44) and of cancer (1.43), and that held even with body mass index accounted for. South Asians carry more visceral fat and less thigh muscle for their body size. A person of normal weight with disproportionate visceral fat is not lean, whatever the chart says.

None of this is a character flaw. Agricultural subsidies make refined carbohydrate and industrial seed oil the cheapest food on the shelf, your first brain, the gut, absorbs the surplus, and the overflow is stored on the road leading out of it, where metaflammation starts.

What does visceral fat have to do with Crohn’s disease?

In Crohn’s disease, fat can wrap the inflamed intestine. Researchers cultured live bacteria from the mesenteric fat of 9 of 11 people with Crohn’s disease, and also from 4 of 4 healthy controls, so bacteria in that fat are expected; the fat is placed to meet them. What differed in Crohn’s was which organisms arrived.

Be clear about the limits. Measura [Cardiometabolic and Autonomic Health Analysis] does not diagnose Crohn’s disease and does not monitor it. It does not replace calprotectin, endoscopy or your gastroenterologist’s plan, which are done elsewhere. If you take a biologic, nothing here is a reason to stop it. Loss of response to anti-TNF drugs runs at about 20.9% per patient-year, so the question is what gets measured and repaired while the drug holds. Measura can add the metabolic picture under the disease, the one nobody on the immune side is charting.

How do you measure visceral fat, and what does each method show?

• Weight and body mass index. A total and a ratio. They cannot locate fat or see muscle, and they are where most visits stop.
• CT or MRI. Imaging sees the visceral compartment directly and was the method behind the cohort above. It is done elsewhere, usually for another reason. If you have had a scan, ask whether the report described visceral fat.
• Body composition. Bioimpedance body composition sends a small, painless electrical signal through the body to estimate fat mass and lean mass separately, so muscle and fat stop hiding inside one number. It is an estimate rather than an image, and its strength is the pattern and the trend across repeat visits.
• Blood work. Laboratory panels show what the depot is doing downstream: fasting glucose and insulin, lipids, liver enzymes and inflammatory markers, the same kinds of values the omental burden tracked in surgical patients.

The non-obvious point is that quieting the signal does not change the depot. In 56 people with metabolic syndrome, the drug etanercept cut C-reactive protein sharply over four weeks, yet body composition and insulin sensitivity did not budge. A lower inflammation number is not a smaller visceral compartment, which is why composition and metabolic labs are worth tracking together. Unmeasured is unmanaged.

What should you ask your doctor about visceral fat?

• Ask which fat has ever been measured, or whether weight is standing in for it. The difference is laid out in body composition, not BMI.
• Ask for fasting insulin alongside glucose. Glucose can stay normal while insulin works harder to hold it there; see insulin resistance and metabolic health.
• If you are South Asian, or diabetes runs in your family, say so at the start of the visit.
• If you have Crohn’s disease, ask who is responsible for your metabolic terrain while the biologic holds the bowel still.
• Ask whether a repeat body composition test can show a trend rather than a single snapshot.

Results go to your physician, who decides what they mean for your care. The book companion, the deep dive on the immune matrix, lists every study above with its limits. Sleep and schedule sit on top of this same terrain, covered in night shift health risks you can measure. In MRI data from more than thirty thousand adults, the same visceral depot tracked how many places hurt, covered in whether belly fat can cause chronic pain.

Frequently asked questions

Can you have too much visceral fat at a normal weight?

Yes. In omental biopsies, inflamed fat went with diabetes rather than body mass index, and in an imaging cohort visceral fat predicted heart disease and cancer after adjusting for body mass index. South Asians tend to carry more of this depot for their size. A normal scale reading is not a measurement of where fat is stored. See why body composition is not the same as weight.

Does bioimpedance measure visceral fat directly?

No. Bioimpedance estimates fat mass and lean mass from how a small electrical signal moves through the body. CT and MRI image the visceral compartment directly but are done elsewhere. Bioimpedance is most useful for separating muscle from fat and for following the same person over time, alongside metabolic blood work. See what a test result can and cannot tell you.

Can Measura tell me whether my Crohn’s disease is flaring?

No. Measura does not diagnose or monitor Crohn’s disease. Flares are assessed by your gastroenterologist with tests done elsewhere. Measura measures the metabolic side, such as body composition and laboratory markers of insulin resistance and inflammation, and sends results to your physician so the terrain under the disease is charted too. See who should be tested.

Why is fat inside the abdomen worse than fat under the skin?

Location changes who hears the signal. Omental fat carried twice the macrophages of fat under the skin in people with obesity, and it drains to the liver, where portal blood held about half again as much interleukin-6 as arterial blood. That burden tracked blood sugar, insulin sensitivity and liver injury. Learn what laboratory panels include.

Should I stop my biologic if my visceral fat is high?

No. Never stop or change a medication because of a measurement without your physician. A biologic holds an inflamed bowel still, and stopping it to test a theory risks the bowel. Visceral fat is a reason to measure and address the terrain alongside the drug, not instead of it. See questions worth asking your doctor.

Is there a way to measure visceral fat at home?

Not with a bathroom scale. Weight is a total and body mass index is a ratio, so neither can show where fat sits or separate it from muscle. CT or MRI sees visceral fat directly. Bioimpedance body composition estimates fat mass and lean mass separately, and blood work shows what the fat is doing downstream. If you have ever had a scan, ask whether the report described visceral fat.

What are signs of high visceral fat?

You may not see it: visceral fat can be inflamed in a person whose scale reading looks ordinary. The signal shows up in blood work, including fasting glucose and insulin, lipids, liver enzymes and inflammatory markers. In surgical patients, the fat inside the abdomen tracked blood sugar, insulin sensitivity and liver injury. If you are South Asian or diabetes runs in your family, measure rather than assume.

What are the worst foods for visceral fat?

Refined carbohydrate and industrial seed oil. Agricultural subsidies make them the cheapest food on the shelf. Your gut absorbs the surplus, and the overflow is stored in the fat along the road leading out of it, the visceral depot that drains to the liver. That is where metaflammation starts. None of this is a character flaw; it is what a cheap food supply delivers.

References

• Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. W. (2003). Obesity is associated with macrophage accumulation in adipose tissue. The Journal of Clinical Investigation, 112(12), 1796-1808. https://doi.org/10.1172/JCI19246
• Cancello, R., Tordjman, J., Poitou, C., Guilhem, G., Bouillot, J. L., Hugol, D., Coussieu, C., Basdevant, A., Bar Hen, A., Bedossa, P., Guerre-Millo, M., & Clement, K. (2006). Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes, 55(6), 1554-1561. https://doi.org/10.2337/db06-0133
• Fontana, L., Eagon, J. C., Trujillo, M. E., Scherer, P. E., & Klein, S. (2007). Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes, 56(4), 1010-1013. https://doi.org/10.2337/db06-1656
• van den Bosch, A. A. S., Kooreman, L., van de Weijer, T., Romano, A., Brecheisen, R., Jin, X., Delvoux, B., Kruitwagen, R. F. P. M., Pijnenborg, J. M. A., & Werner, H. M. J. (2026). Visceral adipose tissue inflammation in endometrial cancer. Cancer Treatment and Research Communications, 48, 101273. https://doi.org/10.1016/j.ctarc.2026.101273
• Britton, K. A., Massaro, J. M., Murabito, J. M., Kreger, B. E., Hoffmann, U., & Fox, C. S. (2013). Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. Journal of the American College of Cardiology, 62(10), 921-925. https://doi.org/10.1016/j.jacc.2013.06.027
• Eastwood, S. V., Tillin, T., Wright, A., Mayet, J., Godsland, I., Forouhi, N. G., Whincup, P., Hughes, A. D., & Chaturvedi, N. (2014). Thigh fat and muscle each contribute to excess cardiometabolic risk in South Asians, independent of visceral adipose tissue. Obesity (Silver Spring, Md.), 22(9), 2071-2079. https://doi.org/10.1002/oby.20796
• Ha, C. W. Y., Martin, A., Sepich-Poore, G. D., Shi, B., Wang, Y., Gouin, K., Humphrey, G., Sanders, K., Ratnayake, Y., Chan, K. S. L., Hendrick, G., Caldera, J. R., Arias, C., Moskowitz, J. E., Ho Sui, S. J., Yang, S., Underhill, D., Brady, M. J., Knott, S., … Devkota, S. (2020). Translocation of Viable Gut Microbiota to Mesenteric Adipose Drives Formation of Creeping Fat in Humans. Cell, 183(3), 666-683.e17. https://doi.org/10.1016/j.cell.2020.09.009
• Qiu, Y., Chen, B.-L., Mao, R., Zhang, S.-H., He, Y., Zeng, Z.-R., Ben-Horin, S., & Chen, M.-H. (2017). Systematic review with meta-analysis: Loss of response and requirement of anti-TNFα dose intensification in Crohn’s disease. Journal of Gastroenterology, 52(5), 535-554. https://doi.org/10.1007/s00535-017-1324-3
• Fain, J. N., Madan, A. K., Hiler, M. L., Cheema, P., & Bahouth, S. W. (2004). Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology, 145(5), 2273-2282. https://doi.org/10.1210/en.2003-1336
• Bernstein, L. E., Berry, J., Kim, S., Canavan, B., & Grinspoon, S. K. (2006). Effects of etanercept in patients with the metabolic syndrome. Archives of Internal Medicine, 166(8), 902-908. https://doi.org/10.1001/archinte.166.8.902

Related reading

• Emulsifiers in Food: What No Test Can Measure About You
• Night Shift Health Risks You Can Actually Measure
• Bioimpedance Body Composition

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.